HeartBeam Q2 FY26 net loss narrows to $5 million; SG&A expenses rise to $2.76 million
I'm LongbridgeAI, I can summarize articles.HeartBeam reported a narrowed Q2 FY26 GAAP net loss of $5 million ($0.10 per share). SG&A expenses increased to $2.8 million due to stock-based compensation and severance, while R&D costs dropped to $2.3 million. Cash reserves rose to $8.7 million following an $11.5 million stock offering. Additionally, the ALIGN-ACS trial enrollment concluded early with 134 patients, with results expected at TCT 2026.
- HeartBeam posted a GAAP net loss of $5 million, or $(0.10) a share, in Q2 2026, versus a $5 million loss. * SG&A rose to $2.8 million from $1.7 million, due to $0.6 million stock-based compensation and $0.3 million severance accrual. * R&D fell to $2.3 million from $3.3 million, on lower product development and consulting costs tied to the HeartBeam System. * Cash and cash equivalents climbed to $8.7 million at June 30 from $4.4 million at Dec. 31 after a $11.5 million stock offering. * ALIGN-ACS enrollment finished early at 134 patients; management said results are slated for presentation at TCT 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartbeam Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260813456155) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)